<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The neuroprotective effects of remacemide <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> ((+/-)-2-amino-N-(1-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1,2-diphenylethyl)<z:chebi fb="0" ids="27856">acetamide</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>) have been assessed with permanent occlusion of one middle cerebral artery in chloralose-anesthetized cats in which key physiologic variables have been monitored throughout the post-ischemic period </plain></SENT>
<SENT sid="1" pm="."><plain>An infusion of remacemide <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> (278 micrograms/kg/min; total dose 25 mg/kg) initiated 90 min prior to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and discontinued at occlusion, reduced significantly (P &lt; 0.02) the volume of ischemic damage (from 2505 +/- 454 mm3 of vehicle-treated cats to 1266 +/- 54 mm3 of remacemide <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>-treated cats) </plain></SENT>
</text></document>